An in vitro tubulogenesis system using cell lines derived from the embryonic kidney shows dependence on multiple soluble growth factors.
Interactions between the ureteric bud (UB) and metanephric mesenchyme are crucial for tubulogenesis during kidney development. Two immortalized cell lines derived from the day 11.5 embryonic kidney, UB cells, which appear to be epithelial (cytokeratin-positive, E-cadherin-positive, and ZO-1-positive by immunostaining) and BSN cells, which are largely mesenchymal (vimentin-positive, but negative for cytokeratin, cell surface E-cadherin, and cell surface ZO-1), were used to establish an in vitro tubulogenesis system. BSN cells expressed hepatocyte growth factor (HGF) and transforming growth factor-beta1 mRNAs, and its conditioned medium (BSN-CM) contained factors capable of activating the epidermal growth factor (EGF) receptor (EGFR). When UB cells were cultured in an extracellular matrix gel in the presence of the embryonic kidney or BSN-CM, the UB cells underwent morphogenetic changes characteristic of early in vitro branching tubulogenesis. These changes were largely inhibited by a combination of neutralizing anti-HGF antibodies and the EGFR inhibitor tyrphostin AG1478, suggesting that EGFR ligands, together with HGF, account for much of this early morphogenetic activity. Nevertheless, there was a significant fraction of tubulogenic activity that could not be inhibited, suggesting the existence of other soluble factors. Whereas HGF, EGF, transforming growth factor alpha, basic fibroblast growth factor (bFGF), and insulin-like growth factor 1 (IGF-1), or a mixture of these growth factors, induced epithelial processes for up to 3 days, only IGF-1, possibly bFGF, and the mixture were able to sustain morphogenesis for longer periods, though not nearly to the same degree as BSN-CM. Moreover, only BSN-CM induced branching tubular structures with clear lumens, consistent with the existence of other soluble factors crucial for the formation and/or maintenance of branching tubular structures with lumens in vitro.
Sakurai
H
H
Renal Division, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02115, USA.
Barros
E J
EJ
Tsukamoto
T
T
Barasch
J
J
Nigam
S K
SK
D000818:Animals; D015415:Biomarkers; D018929:Cell Culture Techniques / Q000379:methods; D002460:Cell Line; D004622:Embryo, Mammalian; D004847:Epithelial Cells; D004848:Epithelium / Q000196:embryology / Q000648:ultrastructure; D005109:Extracellular Matrix; D006133:Growth Substances / Q000494:pharmacology*; D017228:Hepatocyte Growth Factor / Q000096:biosynthesis; D007150:Immunohistochemistry; D007668:Kidney / Q000166:cytology* / Q000196:embryology*; D051379:Mice; D008870:Microtubules / Q000502:physiology* / Q000648:ultrastructure; D009024:Morphogenesis / Q000187:drug effects; D012333:RNA, Messenger / Q000096:biosynthesis; D014158:Transcription, Genetic; D016212:Transforming Growth Factor beta / Q000096:biosynthesis; D014746:Vimentin / Q000032:analysis
D015415:Biomarkers; D006133:Growth Substances; D012333:RNA, Messenger; D016212:Transforming Growth Factor beta; D014746:Vimentin; D017228:Hepatocyte Growth Factor